abs15.txt	in	2017		due	to	a	fluid	shortage	secondary	hurricane	maria's	devastation	ofpuerto	rico	hospitals	and	health-systems	began	substitute	rolapitant	forfosaprepitant	as	part	of	chemotherapy-induced	nausea	vomiting	prevention	andtreatment	strategies	however	despite	advantageous	pharmacologic	formulation(e	g	long	half-life	quicker	time	onset	lack	first-pass	hepaticmetabolism)	profiles	there	seems	be	significant	risk	infusion-relatedhypersensitivity	reactions	associated	with	the	administration	intravenousrolapitant	january	2018	u	s	fda	issued	health	care	provider	letterstating	that	anaphylaxis	anaphylactic	shock	other	serious	hypersensitivityreactions	have	been	reported	postmarketing	setting	importantly	thesereactions	were	observed	at	higher	rate	than	initially	phase	1bioequivalence	study	led	approval	intravenous	(2	8%)	many	resulting	hospitalizations	our	institution	rolapitant-inducedinfusion-related	also	occurred	more	patients	expected	(8	7%)	described	herein	are	six	cases	infusion-related	hypersensitivity	reactionswith	north	carolina	cancer	hospital	thequick	interpatient	differences	pharmacokinetics	or	pharmacodynamics	areunlikely	cause	an	objective	assessment	utilizing	naranjo	causalityscale	rates	these	definite	adversedrug
